Alpine Immune Sciences Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Mitch Gold
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 19.8% |
| CEO tenure | 7.8yrs |
| CEO ownership | n/a |
| Management average tenure | 4.6yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Apr 11Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts
Mar 21
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug
Mar 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up
Feb 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up
Dec 19We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
May 11Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Alpine Immune Sciences drops 13% after hours on $100M stock offering
Sep 20Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Alpine: Rest Before Rallying Again
Apr 25Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18We Think The Compensation For Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) CEO Looks About Right
Jun 03Alpine Immune Sciences files for $150M mixed shelf offering
May 26Alpine Immune Sciences (NASDAQ:ALPN) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$32m |
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$3m | US$544k | -US$58m |
| Sep 30 2022 | n/a | n/a | -US$54m |
| Jun 30 2022 | n/a | n/a | -US$54m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$3m | US$523k | -US$50m |
| Sep 30 2021 | n/a | n/a | -US$42m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$1m | US$500k | -US$28m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$33m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$2m | US$485k | -US$42m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$48m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$1m | US$400k | -US$36m |
| Sep 30 2018 | n/a | n/a | -US$30m |
| Jun 30 2018 | n/a | n/a | -US$15m |
| Mar 31 2018 | n/a | n/a | -US$11m |
| Dec 31 2017 | US$2m | US$300k | -US$8m |
Compensation vs Market: Mitch's total compensation ($USD2.75M) is below average for companies of similar size in the US market ($USD6.59M).
Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.
CEO
Mitch Gold (55 yo)
7.8yrs
Tenure
US$2,748,279
Compensation
Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 7.8yrs | US$2.75m | no data | |
| President and Head of Research & Development | 5yrs | US$2.72m | 0.037% $ 1.6m | |
| Senior VP | 7yrs | US$1.61m | no data | |
| VP of Finance & Chief Accounting Officer | no data | no data | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Business Officer | 4.3yrs | no data | 0.011% $ 446.0k | |
| Chief Medical Officer | less than a year | no data | no data |
4.6yrs
Average Tenure
52yo
Average Age
Experienced Management: ALPN's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 9.3yrs | US$2.75m | no data | |
| Independent Director | 6.8yrs | US$150.80k | 0.076% $ 3.2m | |
| Independent Director | 7.8yrs | US$142.05k | 0% $ 0 | |
| Independent Director | 7.8yrs | US$144.55k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Independent Director | 5.3yrs | US$140.80k | 0% $ 0 | |
| Scientific Advisory Board Chairman | no data | no data | no data | |
| Independent Director | 6yrs | US$139.55k | 0.0029% $ 122.9k | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 5.4yrs | no data | no data |
6.0yrs
Average Tenure
58yo
Average Age
Experienced Board: ALPN's board of directors are considered experienced (6 years average tenure).